Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Acetaminophen Injection, 1,000 mg/ 100 mL single-dose vial (SDV). Aurobindo's Acetaminophen Injection is a generic equivalent of Mallinckrodt's Ofirmev Injection.
The product will be launched in December 2020.
Acetaminophen Injection is indicated for the treatment of mild to moderate pain in adult and pediatric patients 2 years and older. The injection is also set to treat moderate to severe pain with adjunctive
opioid analgesics in adult and pediatric patients 2 years and older, and reduction of fever in adult and pediatric patients. The approved product has an estimated market size of US$ 339 million for the twelve
months ending August 2020 according to IQVIA.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.